{'52WeekChange': 0.48283505,
 'SandP52WeekChange': 0.0644362,
 'address1': '35 Gatehouse Drive',
 'address2': 'Building D Floor 3',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.47,
 'askSize': 900,
 'averageDailyVolume10Day': 240500,
 'averageVolume': 954600,
 'averageVolume10days': 240500,
 'beta': 1.83032,
 'beta3Year': None,
 'bid': 13.11,
 'bidSize': 900,
 'bookValue': 1.769,
 'category': None,
 'circulatingSupply': None,
 'city': 'Waltham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.49,
 'dayLow': 13.05,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.973,
 'enterpriseToRevenue': 265.353,
 'enterpriseValue': 402541088,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '781 419 1420',
 'fiftyDayAverage': 15.116143,
 'fiftyTwoWeekHigh': 21.97,
 'fiftyTwoWeekLow': 5.35,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 24218615,
 'forwardEps': -1.82,
 'forwardPE': -7.357143,
 'fromCurrency': None,
 'fullTimeEmployees': 35,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.08083,
 'heldPercentInstitutions': 0.56569,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/syndax.com',
 'longBusinessSummary': 'Syndax Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, develops therapies for the '
                        "treatment of cancer. The company's lead product "
                        'candidates are entinostat that is in Phase III '
                        'clinical trials for the treatment of advanced hormone '
                        'receptor positive (HR+), human epidermal growth '
                        'factor receptor 2 negative (HER2-) breast cancer; and '
                        'SNDX-5613 in Phase I/II clinical trial inhibitor that '
                        'targets the binding interaction of Menin with mixed '
                        'lineage leukemia-rearranged and acute myeloid '
                        'leukemia with a mutated nucleophosmin 1. It also '
                        'develops entinostat with Keytruda (pembrolizumab) in '
                        'a Phase Ib/II clinical trials for the treatment of '
                        'non-small cell lung cancer and melanoma or '
                        'microsatellite stable colorectal carcinoma; and with '
                        'Tecentriq (atezolizumab) in Phase Ib/II clinical '
                        'trials to treat patients with HR+ and HER2- '
                        'metastatic breast cancer. In addition, the company '
                        'develops SNDX-6352, a monoclonal antibody that blocks '
                        'the colony stimulating factor 1 that is in Phase I/II '
                        'clinical trial in patients with chronic graft versus '
                        'host disease; and as a monotherapy and in combination '
                        'with Imfinzi (durvalumab), which is completed Phase '
                        'Ib dose trials for the treatment of solid tumors. '
                        'Syndax Pharmaceuticals, Inc. has clinical '
                        'collaborations with MSD International GmbH; '
                        'Genentech, Inc.; and Merck KGaA and Pfizer. It also '
                        'has collaborative research and development agreement '
                        'with National Cancer Institute; clinical trial '
                        'agreement with Eastern Cooperative Oncology Group; '
                        'and license agreement with Kyowa Hakko Kirin Co., '
                        'Ltd. The company was founded in 2005 and is '
                        'headquartered in Waltham, Massachusetts.',
 'longName': 'Syndax Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 483310720,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_27240138',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -60887000,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.41,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781 419 1400',
 'previousClose': 13.55,
 'priceHint': 2,
 'priceToBook': 7.569248,
 'priceToSalesTrailing12Months': 318.59637,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.49,
 'regularMarketDayLow': 13.05,
 'regularMarketOpen': 13.41,
 'regularMarketPreviousClose': 13.55,
 'regularMarketPrice': 13.41,
 'regularMarketVolume': 186249,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 36094900,
 'sharesPercentSharesOut': 0.1058,
 'sharesShort': 3818173,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2892408,
 'shortName': 'Syndax Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1177,
 'shortRatio': 7.39,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'SNDX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.884,
 'twoHundredDayAverage': 12.667842,
 'volume': 186249,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.syndax.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02451'}